Remember
 
 
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.

Fighting Cancer Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Fighting Cancer Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: cancer, oncology, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Fighting Cancer.

Generated with SpeculatingStocks Stock Theme Analytics Algorithmâ„¢ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to fighting cancer; however, a few may just somewhat depend and/or be indirectly related to fighting cancer. As always complete your own due diligence.


Fighting Cancer Stocks & ETFs


Symbol
Company / ETF Name
Market Cap





















































350.343M

























































































































































































Recent Fighting Cancer Headlines





Recent Fighting Cancer Posts (Pulses)




05/17/2018: $REGN Regeneron and Sanofi Share first positive clinical data for Cemiplimab in advanced non-small cell lung cancer at ASCO. -- Go to this Pulse Post



05/17/2018: $ABBV AbbVie will present data about its portfolio of investigational oncology medicines at ASCO annual meeting. -- Go to this Pulse Post



05/17/2018: $IMMU Immunomedics reported 'positive' data for sacituzumab govitecan, its metastatic breast cancer drug. -- Go to this Pulse Post



05/16/2018: $REGN Regeneron and Sanofi Share first positive clinical data for Cemiplimab in advanced non-small cell lung cancer at ASCO. -- Go to this Pulse Post



05/16/2018: $ABBV AbbVie will present data about its portfolio of investigational oncology medicines at ASCO annual meeting. -- Go to this Pulse Post



05/16/2018: $IMMU Immunomedics reported 'positive' data for sacituzumab govitecan, its metastatic breast cancer drug. -- Go to this Pulse Post



05/09/2018: $ECYT Endocyte announced The Lancet Oncology publication of data on 30 patients with PSMA-positive metastatic castration-resistant prostate cancer treated with Lu-PSMA-617. -- Go to this Pulse Post



05/04/2018: $MRK Merck and Moderna Therapeutics Moderna Therapeutics announced an expansion of their 2016 collaboration to develop and commercialize novel personalized messenger RNA (mRNA) cancer vaccines to now include shared antigen mRNA cancer vaccines including mRNA-5671. -- Go to this Pulse Post



05/04/2018: $EDIT Editas Medicine up 9% after expanding Celgene (CELG) collaboration to drive lead oncology program in solid tumors. -- Go to this Pulse Post



05/03/2018: $MRK Merck and Moderna Therapeutics Moderna Therapeutics announced an expansion of their 2016 collaboration to develop and commercialize novel personalized messenger RNA (mRNA) cancer vaccines to now include shared antigen mRNA cancer vaccines including mRNA-5671. -- Go to this Pulse Post



05/03/2018: $BMY Bristol-Myers: EMA validated a type II variation application for the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination for treatment in adult patients with first-line metastatic non-small cell lung cancer (NSCLC) who have tumor mutational burden (TMB) 10 mutations/megabase (mut/Mb. -- Go to this Pulse Post



04/27/2018: $IMGN Immunogen announced that the FORWARD I Phase 3 registration trial evaluating mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer will continue as planned without modification. -- Go to this Pulse Post



04/26/2018: $IMGN Immunogen announced that the FORWARD I Phase 3 registration trial evaluating mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer will continue as planned without modification. -- Go to this Pulse Post



04/26/2018: $ADRO Aduro Biotech presented observations from a case study of a patient with metastatic colorectal cancer treated in Aduro's ongoing Phase 1 study of its personalized neoantigen-based immunotherapy. -- Go to this Pulse Post



04/24/2018: $NKTR Nektar Therapeutics entered into a new clinical collaboration with Takeda Pharmaceutical (TKPYY) to evaluate Nektar's investigational medicine, NKTR-214, with Takeda's investigational medicine, TAK-659, as a potential combination treatment regimen in multiple cancer settings. -- Go to this Pulse Post



04/24/2018: $TSRO Tesaro announced positive top-line results from Quadra trial of ZEJULA; results demonstrate ZEJULA activity beyond patients with BRCA mutations in late-line ovarian cancer treatment setting. -- Go to this Pulse Post



04/19/2018: $BMY Bristol-Myers announced that the FDA accepted for priority review its supplemental Biologics License Application for Opdivo (nivolumab) to treat patients with small cell lung cancer who have received two or more lines of previous treat; action date is August 16, 2018. -- Go to this Pulse Post



04/18/2018: $BMY Bristol-Myers announced that the FDA accepted for priority review its supplemental Biologics License Application for Opdivo (nivolumab) to treat patients with small cell lung cancer who have received two or more lines of previous treat; action date is August 16, 2018. -- Go to this Pulse Post



04/16/2018: $ILMN Illumina and Bristol-Myers (BMY) to develop/commercialize companion diagnostics for Bristol-Myers' oncology immunotherapies; expanded Illumina's oncology offerings for NextSeq 550Dx. -- Go to this Pulse Post



04/16/2018: $TSRO Tesaro summarizes presentation of initial data from the Phase 1 GARNET trial of TSR-042 in patients with microsatellite instability high endometrial cancer and non-small cell lung cancer. -- Go to this Pulse Post



04/16/2018: $BMY Bristol-Myers announced initial results from pivotal Phase 3 study (CheckMate -227) evaluating Opdivo 3 mg/kg plus low-dose Yervoy combination in first-line advanced non-small cell lung cancer patients with high tumor mutational burden 10 mutations/megabase. -- Go to this Pulse Post



04/16/2018: $FATE Fate Therapeutics to feature off-the-shelf CAR T-cell cancer immunotherapy, FT819, at 2018 AACR Annual Meeting Press Program. -- Go to this Pulse Post



04/16/2018: $SHPG Shire plc announced sale of oncology business to Servier for $2.4 Billion. -- Go to this Pulse Post



04/13/2018: $ILMN Illumina and Bristol-Myers (BMY) to develop/commercialize companion diagnostics for Bristol-Myers' oncology immunotherapies; expanded Illumina's oncology offerings for NextSeq 550Dx. -- Go to this Pulse Post



04/09/2018: $CPIX Cumberland Pharma expanded into oncology support. -- Go to this Pulse Post



04/06/2018: $CLVS Clovis Oncology confirmed FDA approval for Rubraca tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. -- Go to this Pulse Post



04/04/2018: $PFE Pfizer announced that the FDA & EMA have accepted the regulatory submissions for review of Dacomitinib to treat metastatic non-small cell lung cancer with EGFR-activating mutations. -- Go to this Pulse Post